ArticleCardiovascular drugs and therapy2021

Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases.

Mei-Chuan Lee et al.PubMed ↗Publisher ↗

No numbers read from the abstract.